Acne Vulgaris Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | AbbVie Inc, AnaptysBio, AOBiome, Ascletis, Bayer, BioPharmX, Botanix, Cassiopea, Dermavant Sciences, DermResearch

 Breaking News
  • No posts were found

Acne Vulgaris Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | AbbVie Inc, AnaptysBio, AOBiome, Ascletis, Bayer, BioPharmX, Botanix, Cassiopea, Dermavant Sciences, DermResearch

September 28
21:29 2023
Acne Vulgaris Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | AbbVie Inc, AnaptysBio, AOBiome, Ascletis, Bayer, BioPharmX, Botanix, Cassiopea, Dermavant Sciences, DermResearch
Delveinsight Business Research LLP
As per DelveInsight, the Acne Vulgaris Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Acne Vulgaris and the launch of new therapies in the market.

DelveInsight’s “Acne Vulgaris Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acne Vulgaris market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Acne Vulgaris drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Acne Vulgaris treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Acne Vulgaris: An Overview

Acne vulgaris is an inflammatory disorder of pilosebaceous unit, which runs a chronic course, and it is self-limiting. Acne vulgaris is triggered by propionibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone.

Acne vulgaris is triggered by Cutibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone (DHEA). It is a very common skin disorder that can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back.

Acne Vulgaris Market Key Facts

  • As per Bhate et al. (2013), moderate-to-severe acne affects around 20% of young people and severity correlates with pubertal maturity.

  • As per Wolkenstein et al. (2018), the self-declared prevalence of acne is relatively high in European adolescents, even if there are variations across countries. Heredity is the main identified risk factor for developing, whereas age is negatively associated with the prevalence of this condition.

  • Some of the key companies such as Galderma SA, Bausch Health Companies Inc, GSK plc, AbbVie Inc, Sun Pharmaceutical Industries Ltd, Cosmo Pharmaceuticals NV, DermResearch Inc, Maruho Co Ltd, TKL Research Inc, Bayer AG, and others are developing therapies for Acne Vulgaris.

Acne Vulgaris Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Acne Vulgaris pipeline therapies. It also thoroughly assesses the Acne Vulgaris market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Acne Vulgaris drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Acne Vulgaris Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Acne Vulgaris epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Acne Vulgaris epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Acne Vulgaris Epidemiology, Segmented as –

  • Total Prevalent Cases of Acne Vulgaris in the 7MM from 2019 to 2032

  • Severity-specific Prevalence of Acne Vulgaris in the 7MM from 2019 to 2032

  • Gender-specific Prevalence of Acne Vulgaris in the 7MM from 2019 to 2032

  • Total Diagnosed and Treatable cases of Acne Vulgaris in the 7MM from 2019 to 2032

Acne Vulgaris Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Acne Vulgaris market or expected to be launched during the study period. The analysis covers the Acne Vulgaris market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Acne Vulgaris drugs based on their sale and market share.

The report also covers the Acne Vulgaris pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Acne Vulgaris companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Acne Vulgaris Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/acne-vulgaris-av-market

Acne Vulgaris Therapeutics Analysis

Various medications and therapies have proven to be effective by targeting the underlying factors that contribute to acne. Using one or a combination of several, depending on the severity of the condition, can prove effective. A well-known treatment for acne is the antibacterial agent benzoyl peroxide, as it reduces the risk of bacterial resistance.

To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Acne Vulgaris. Currently, Bausch Health America is leading the therapeutics market with its Acne vulgaris drug candidates in the most advanced stage of clinical development.

Acne Vulgaris Companies Actively Working in the Therapeutics Market Include

AbbVie Inc, AnaptysBio, Inc., AOBiome LLC, Ascletis Pharmaceuticals, Bausch Health Companies Inc, Bayer AG, BioPharmX, Boston Pharmaceuticals, Botanix Pharmaceuticals, Cassiopea, Inc., Cosmo Pharmaceuticals NV, Dermavant Sciences, DermResearch Inc, Eligo Bioscience, Galderma SA, GSK plc, Kintor Pharma, Madam Therapeutics, Maruho Co Ltd, Novan, Inc., Origimm Biotechnology, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, SiSaf, Sun Pharmaceutical Industries Ltd, TKL Research Inc, Xenon Pharmaceuticals Inc., and others.

Emerging and Marketed Acne Vulgaris Therapies Covered in the Report Include:

  • IDP126: Bausch Health Americas, Inc.

  • DMT310: Dermata Therapeutics

  • BPX-01 – BioPharmX

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/acne-vulgaris-av-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Acne Vulgaris Competitive Intelligence Analysis

4. Acne Vulgaris Market Overview at a Glance

5. Acne Vulgaris Disease Background and Overview

6. Acne Vulgaris Patient Journey

7. Acne Vulgaris Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Acne Vulgaris Treatment Algorithm, Current Treatment, and Medical Practices

9. Acne Vulgaris Unmet Needs

10. Key Endpoints of Acne Vulgaris Treatment

11. Acne Vulgaris Marketed Therapies

12. Acne Vulgaris Emerging Drugs and Latest Therapeutic Advances

13. Acne Vulgaris Seven Major Market Analysis

14. Attribute Analysis

15. Acne Vulgaris Market Outlook (In US, EU5, and Japan)

16. Acne Vulgaris Companies Active in the Market

17. Acne Vulgaris Access and Reimbursement Overview

18. KOL Views on the Acne Vulgaris Market

19. Acne Vulgaris Market Drivers

20. Acne Vulgaris Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/acne-vulgaris-av-market

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Invasive Pneumococcal Disease Market

“Invasive Pneumococcal Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Invasive Pneumococcal Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Invasive Pneumococcal Disease market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology

Related Articles

Categories